Is first Solar a cash burner

I am Wondering if it is still time to buy


Good sense tells me to avoid falling stocks

How much is Arena Pharmaceuticals worth

Belviq sales are low

Arena is all about expectactions on the pipeline


About APD334
APD334 is a potent and selective, orally available investigational drug candidate that targets the S1P₁ receptor. Discovered by Arena, APD334 has therapeutic potential in autoimmune diseases such as ulcerative colitis. S1P₁ receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating subpopulations of lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage.

Phase 2 Clinical Trial of APD334

The odds of going to phase3 are high if so Arena will be a unicorn soon

O Regresso do Rei da Bolsa

The stock market king returns to Portugal